protein FAM153CGenealiases: FAM153C · NY-REN-7-like
Q-omics provides the consensus-scored FAM153CP profile across patient tissues and cancer cell-line models. FAM153CP expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAM153CP is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, FAM153CP RNA expression shows 17,023 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where FAM153CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM153CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM153CP survival associations across molecular data types. FAM153CP RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM153CP RNA expression–survival associations across cancer types. High FAM153CP expression shows unfavorable associations in UVM and ESCA, but favorable associations in HNSC, READ, KIRP and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FAM153CP RNA expression.
This table summarizes FAM153CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM153CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM153CP shows lower tumor expression in LUAD, LUSC, UCEC and THCA and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher FAM153CP RNA expression in tumor versus normal tissue (log2 FC = +0.863, t-test p < 0.001).
This table shows molecular features associated with FAM153CP in patient tissues and cancer cell lines. In patient samples, FAM153CP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM153CP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma.
